L
Lutetium-177 peptide
Availability of ACE Drug Guidance
No
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Active ingredient: Lutetium (177-Lu) Oxodotreotide
General information
Subsidy Information and Financing Scheme
[MSHL] Lutetium-177 peptide 177-Lu peptide
Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G
, somatostatin receptor-positive gastro-entero-pancreatic neuroendocrine tumours (NETs), including foregut, midgut, and hindgut NETs.
Drug Guidance for Subsidy
Not Applicable
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Intravenous
* Clinical information is available for this product.